Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a majority stake in the clinical-stage company and replacing its CEO.

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed. Aurion will operate as ...

11,20 “I was excited to learn that Alcon evolved this leading technology for more light utilization and less light scatter.1,2,* My early patient results with PanOptix Pro support that this ...